Midatech Pharma Plc Gross Profit

The latest gross profit for MTP is $-6.1M as of December 2025. That compares with $-4.2M in the prior-year period — down 42.9% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Midatech Pharma Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, MTP's gross profit moved from $-4.2M to $-6.1M — a 42.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Midatech Pharma Plc's operating scale or balance-sheet position.

Against Healthcare companies, MTP currently prints $-6.1M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Midatech Pharma Plc's growth, margins, and balance sheet.

A gross profit figure of $-6.1M for MTP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting MTP's gross profit ($-6.1M), review year-over-year change from $-4.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.